Ortho Pharmaceutical

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Safety, Upjohn, RNA interference, Alnylam Pharmaceuticals, Patient, Chicago (franchise), U.S. Securities and Exchange Commission, Therapeutic index, Leadership, NASDAQ, Research, International law, Atlas Venture, Time, Cytokine, COVID-19, Orbital, Investment, Johnson & Johnson, Biochemistry, Tumor microenvironment, SEC, Takeda Oncology, Patent, Molecular biology, J&J, Atlas, Master of Laws, Agios Pharmaceuticals, Goal, Janssen, GLOBE, Biotechnology Innovation Organization, Immune system, Biogen, GPS, Therapy, Twitter, University of Antwerp, LinkedIn, Private Securities Litigation Reform Act, Cancer, Ortho Pharmaceutical, RNA, Biotechnology, R, University, Pharmaceutical industry, Management, ZymoGenetics, MorphoSys

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the companys board of directors.

Key Points: 
  • WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the companys board of directors.
  • The collective experience of Tom and John will be highly valuable as Xilio continues to advance its innovative scientific platform and promising pipeline of tumor-selective immunotherapy programs, said Paul Clancy, chair of the board of directors of Xilio Therapeutics.
  • Mr. Heyman currently serves as a member of the boards of directors of Legend Biotech, Akero Therapeutics, OptiNose, and Adagio Therapeutics.
  • He is chair of the board of directors of Hemab Therapeutics and the chairman and co-founder of Orbital Therapeutics.

Tim Hale Joins THinc Partners Automated Retail Consulting Team

Retrieved on: 
Tuesday, January 11, 2022
Traction, Industry, Automated retail, Marketing, Ortho Pharmaceutical, Management, Retail, Redbox

KNOXVILLE, Tenn., Jan. 11, 2022 /PRNewswire-PRWeb/ --Thomas-Hendrickson Inc. (THinc Partners), a leading management consulting firm specializing in automated retail, today announced the addition of Tim Hale as senior strategic advisor.

Key Points: 
  • KNOXVILLE, Tenn., Jan. 11, 2022 /PRNewswire-PRWeb/ --Thomas-Hendrickson Inc. (THinc Partners), a leading management consulting firm specializing in automated retail, today announced the addition of Tim Hale as senior strategic advisor.
  • Hale's extensive industry experience in brick-and-mortar retail, automated retail, and corporate executive team leadership further strengthens THinc Partners collective skill set.
  • "Automated Retail done well captures consumer loyalty with the potential of increasing consumer trips and spend for retailers," said Hale.
  • Thomas-Hendrickson Inc. is a leading management consulting firm that specializes in automated retail.

Mayne Pharma launches another generic oral contraceptive

Retrieved on: 
Thursday, March 4, 2021
Combined oral contraceptives, Drugs, Health care, Ethinylestradiol/etonogestrel, Pharmacology, Combined oral contraceptive pill, Birth control pill formulations, Ortho, Estetrol/drospirenone, Generic drug, Ortho Pharmaceutical

This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.

Key Points: 
  • This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.
  • Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives.
  • Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options.
  • "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS (E4/DRSP) and a generic version of NUVARING.